期刊文献+

紫杉醇联合5-氟尿嘧啶及亚叶酸钙治疗29例晚期胃癌 被引量:8

下载PDF
导出
摘要 目的观察紫杉醇联合5-氟尿嘧啶/亚叶酸钙治疗晚期胃癌的疗效和不良反应。方法 29例晚期胃癌的患者,应用紫杉醇联合5-氟尿嘧啶/亚叶酸钙治疗:紫杉醇135~175 mg/m2,静脉滴注3 h以上,第1天,亚叶酸钙400 mg/m2,静脉滴注2 h,第1天,随后5-氟尿嘧啶375 mg/m2静脉推注10 min,再将2 500 mg/m2加入输液泵中持续静脉滴注48~52 h。每3周重复,至少2周期。结果 29例均可评价,总有效率为44.8%,其中完全缓解1例(3.4%),部分缓解12例(41.4%),稳定10例(34.5%),进展6例(20.7%),中位生存期9.6个月。不良反应主要为骨髓抑制、肌肉关节痛、外周神经炎和脱发,但均可耐受。结论紫杉醇联合5-氟尿嘧啶/亚叶酸钙治疗晚期胃癌疗效较好,不良反应可耐受。
出处 《广东医学》 CAS CSCD 北大核心 2011年第13期1760-1761,共2页 Guangdong Medical Journal
  • 相关文献

参考文献2

二级参考文献31

  • 1张思维,陈万青,孔灵芝,李连弟,鲁凤珠,李光琳,孟佳,赵平.中国部分市县1998~2002年恶性肿瘤的发病与死亡[J].中国肿瘤,2006,15(7):430-448. 被引量:171
  • 2邹淑蓉,施爱珍,高围溦,宓铭,程娜,姜培珍,宋峻,陈敏,刘弘.上海市居民膳食结构变化趋势分析[J].上海预防医学,2006,18(7):311-314. 被引量:30
  • 3屈涛.血清半胱氨酸、维生素B2水平与食管癌及胃贲门癌相关[J].中国医学论坛报,肿瘤专刊,2001,.
  • 4李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
  • 5WHO. 1994 World Health Statistics Annual. Geneve: WHO, 1995 ,B4-B347.
  • 6Limburg P, Qiao Y, Mark S, et al. Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. J Natl Cancer.Inst, 2001,93:226-233.
  • 7Pisani P, Parkin DM, Ferlay J, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer, 1999,83: 18-29.
  • 8WHO. 1973-1976 World Health Statistics Annual. Geneve: WHO,1976. 188-719.
  • 9Parkin DM, Whelan S, Ferlay J, et al. Cancer Incidence in Five Continents[CP]. Vol I-VIII.IARC CancerBase,No 7,Lyon,2005.
  • 10Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin,2005,55(2):74-108.

共引文献796

同被引文献44

  • 1Van Cutsem E,Moiseyenko VM,Tjulandin S,et al.Phase III Studyof Docetaxel and Cisplatin Plus Fluorouracil Compared WithCisplatin and Fluorouracil As First-Line Therapy for AdvancedGastric Cancer:A Report of the V325 Study Group[J].J Clin Oncol,2006,24(31):4991-4997.
  • 2Thuss-Patience PC,Kretzschmar A,Bichev D,et al.Survivaladvantage for irinotecan versus best supportive care as second-linechemotherapy in gastric cancer--a randomised phase III study ofthe Arbeitsgemeinschaft Internistische Onkologie(AIO)[J].Eur JCancer,2011,47(15):2306-2314.
  • 3PAPAK05TA5 P, T5AVDARIDI5 D, K05MIDI5 P, et al. Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group Phase II Studv[J]. Gastric Cancer, 2006, 9(1):26-31.
  • 4PAPAKOSTAS P, TSAVDARIDIS D, KOSMIDIS P, et al. Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group Phase II Study[J]. Gastric Cancer, 2006, 9(1):26-31.
  • 5JEUNG H C, RHA 5 Y, KIM Y T, et al. A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer[J], Oncology, 2006, 70(1):63-70.
  • 6YAMAGUCHI K, 5HIMAMURA T, HYODO I, et al. Phase I / II study of docetaxel and 5-1 in patients with advanced gastric cancer[J], Br J Cancer, 2006, 94(12): 1803-1808.
  • 7YOSHIDA K, NINOMIYA M, TAKAKURA N, et al. Phase II study of docetaxel and 5-1 combination therapy for advanced or recurrent gastric cancer[J]. Clin Cancer Res, 2006, 12(11 Pt1):3402-3407.
  • 8PARK 5 R, KIM H K, KIM C G, et al. Phase I / II study of 5-1 combined with weekly docetaxel in patients with metastatic gastric carcinorna[J], Br J Cancer, 2008, 98(8): 1305-1311.
  • 9AJANI J A, RODRIGUEZ W, BODOKY G, et al. Multicenter phase III comparison of clsplattn/Se l with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial[J]. J Clin Oncol, 2010, 28(9):1547-1553.
  • 10南京中医药大学.中药大辞典[M].上海:上海科学技术出版社,2012:23-24.

引证文献8

二级引证文献106

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部